End-of-life ethics
What ethics does a permanent heart pump raise?
Open access · cc by · source: Europe PMC
LVAD as destination therapy prolongs life in transplant-ineligible heart failure, but it also reshapes dying, consent, and caregiver burden.
Key findings
LVAD-DT is intended to prolong survival and improve quality of life, yet complications and caregiver load can alter the dying trajectory. Consent must protect autonomy. Deactivation to allow death is discussed alongside the idea that withdrawing support can be morally equivalent to never starting it.
Methodology
The authors re-read survival and complication data from LVAD-DT trials (including REMATCH) and organise the ethical issues around informed consent, caregiver effects, and turning the device off near the end of life.
Limitations
This is not a new RCT. REMATCH numbers are cited from prior trials. It does not settle when a particular patient should refuse or deactivate a pump.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
LVAD as destination therapy prolongs life in transplant-ineligible heart failure but reshapes dying, consent and caregiver burden.
Evidence for the claim as stated.
Related papers in this topic
Same topic cluster — not a recommendation engine.